TY - JOUR T1 - A Novel Formulation of an Ophthalmic Beta-Adrenoceptor Antagonist JF - PDA Journal of Pharmaceutical Science and Technology JO - PDA J Pharm Sci Technol SP - 51 LP - 53 VL - 46 IS - 2 AU - Robert N. Weinreb AU - Rajni Jani Y1 - 1992/03/01 UR - http://journal.pda.org/content/46/2/51.abstract N2 - To minimize ocular discomfort while maintaining efficacy, a delivery system for a topical cardioselective β-adrenoceptor antagonist, betaxolol was developed. Betaxolol was formulated at 0.25% concentration in a cationic exchange resin, as a suspension. A polyacrylic acid polymer was added to increase viscosity and to increase residence time in the cul-de-sac. No significant settling was observed throughout a four-week observation period. Thus, resuspension of the formulation by frequent shaking was not required for uniformity. In rabbits, the ocular bioavailability of 0.25% betaxolol suspension was equivalent to that of 0.5% betaxolol solution. ER -